Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2000 participants.
Also called NCT01613729
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,000 participants
- Sponsor
- D16 Pharma & Biotec Ltd.
- Registry
-
NCT01613729
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Bangladesh
- Registry status
- Unknown status
Technical summary
Registry record NCT01613729. Randomized; no masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2013-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin
- Acronym
- Cor16
- Condition
- Dyslipidemia
- Intervention (Drug)
- Rosuvastatin 5 mg
- Intervention (Drug)
- Rosuvastatin 10 mg
- Lead sponsor
- D16 Pharma & Biotec Ltd.
- Collaborator
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Collaborator
- Dhaka Medical College
- Collaborator
- National Institute of Cardiovascular Diseases
Record details
- Record id
cardio:ct-nct01613729- Content hash
728300aae1d375876831ac30e0b1e22a445a4a97eb7a878b8f632e32d9c9f505